Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.67 |
| ▸ | ACE | P12821 | 3/20 | 0.61 |
| ▸ | ECE1 | P42892 | 12/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29429568 | 0.91 | ACE (0.67) | ERAP2ACEECE1ALOX15 | |
| Oglufanide SCHEMBL1898073 | 0.91 | ERAP2 (0.68) | ERAP2ACEECE1ALOX15 | |
| Oglufanide SCHEMBL5822559 | 0.91 | ERAP2 (0.68) | ERAP2ACEECE1ALOX15 | |
| Oglufanide SCHEMBL5735529 | 0.91 | ERAP2 (0.68) | ERAP2ACEECE1ALOX15 | |
| Oglufanide SCHEMBL2042188 | 0.91 | ERAP2 (0.68) | ERAP2ACEECE1ALOX15 | |
| Oglufanide SCHEMBL24454642 | 0.91 | ERAP2 (0.68) | ERAP2ACEECE1ALOX15 | |
| Oglufanide SCHEMBL3053743 | 0.91 | ERAP2 (0.68) | ERAP2ACEECE1ALOX15 | |
| Oglufanide SCHEMBL1898076 | 0.91 | ERAP2 (0.68) | ERAP2ACEECE1ALOX15 | |
| Oglufanide SCHEMBL5822555 | 0.91 | ERAP2 (0.68) | ERAP2ACEECE1ALOX15 | |
| SCHEMBL29603769 | 0.91 | ERAP2 (0.62) | ERAP2ACEECE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240352073-A1 | BICYCLIC PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | JANSSEN BIOTECH INC (US) | 2024-10-24 | — | — | US | disclosed |
| WO-2023288017-A2 | BICYCLIC PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | JANSSEN BIOTECH, INC. (US) | 2023-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240352073-A1 | BICYCLIC PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | IL23R, IL1RN, IL17A | ERAP2 522/4885ACE 1092/4885ECE1 1508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.